Decrease in Aβ42 predicts dopa-resistant gait progression in early Parkinson disease
Citation Manager Formats
Make Comment
See Comments
This article has a correction. Please see:

Abstract
Objective: This prospective observational study investigates the role of CSF biomarkers in predicting progression of dopa-resistant gait impairments in Parkinson disease (PD) in the first 36 months from diagnosis.
Methods: Quantitative gait analysis was carried out longitudinally using an instrumented walkway (GAITRite) in 108 people with PD and 130 age-matched controls. A subgroup of 44 people with PD underwent lumbar puncture from which a battery of CSF biomarkers was measured: β-amyloid 1–42 and 1–40 (Aβ42 and Aβ40), total and phosphorylated tau protein (t-tau/p-tau181), and α-synuclein (αSyn). Linear mixed models examined the association between CSF and dopa-resistant gait characteristics (defined as substantial progression despite optimal medication).
Results: Low baseline CSF Aβ42, and to a lesser extend Aβ40, predicted decline in gait characteristics in the first 3 years following diagnosis, independently explaining up to 12% of progression of step time variability (single task) and step length variability (dual-task). Interestingly, these findings were independent of age and cognition.
Conclusions: These findings implicate underlying amyloid pathology in neural networks involved in locomotor control. Results suggest that disturbed Aβ metabolism may be a biomarker for dopa-resistant gait impairments in early PD. Our findings raise interesting questions regarding therapeutic interventions such as compounds or molecules aimed at reducing amyloid burden to mitigate gait disturbance in early PD and potentially falls risk. Finally, progression of discrete gait characteristics suggests they may have potential as clinical biomarkers of pathology and disease progression.
GLOSSARY
- αSyn=
- α-synuclein;
- Aβ=
- β-amyloid;
- ICICLE=
- Incidence of Cognitive Impairment in Cohorts with Longitudinal Evaluation;
- LEDD=
- levodopa equivalent dose;
- LP=
- lumbar puncture;
- MoCA=
- Montreal Cognitive Assessment;
- PD=
- Parkinson disease;
- PIGD=
- postural instability and gait
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing Charge was funded by Parkinson's UK.
Supplemental data at Neurology.org
- Received August 24, 2016.
- Accepted in final form December 12, 2016.
- Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Letters: Rapid online correspondence
- AB42 and glymphatics
- Joseph W. McSherry, Physician, RLCoM at UVMjoe.mcsherry@uvmhealth.org
Submitted June 16, 2017
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. David E. Vaillancourt and Dr. Shannon Y. Chiu
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Article
Reduced cognitive function in patients with Parkinson disease and obstructive sleep apneaVictoria P. Mery, Priti Gros, Anne-Louise Lafontaine et al.Neurology, February 22, 2017 -
Articles
Methylphenidate for gait impairment in Parkinson diseaseA randomized clinical trialA.J. Espay, A.K. Dwivedi, M. Payne et al.Neurology, April 04, 2011 -
Article
Gait analysis in PSP and NPHDual-task conditions make the differenceCharlotte Selge, Florian Schoeberl, Andreas Zwergal et al.Neurology, February 21, 2018 -
Article
Association of Physical Activity and APOE Genotype With Longitudinal Cognitive Change in Early Parkinson DiseaseRyul Kim, Sangmin Park, Dallah Yoo et al.Neurology, March 31, 2021